Portage Biotech Announces Collaboration With Merck To Evaluate Two Next-Generation Adenosine Antagonists In Combination With KEYTRUDA In Solid Tumors
Portfolio Pulse from Happy Mohamed
Portage Biotech Inc. (NASDAQ:PRTG) has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate Portage's next-generation adenosine antagonists in combination with KEYTRUDA, Merck's anti-PD-1 therapy, for patients with solid tumors. The collaboration will explore Portage's adenosine 2A receptor (A2AR) antagonist, PORT-6, its adenosine 2B receptor (A2BR) antagonist, PORT-7, individually and together in combination with KEYTRUDA in various cancers.
September 05, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's collaboration with Portage Biotech to evaluate the latter's next-generation adenosine antagonists in combination with KEYTRUDA could potentially expand its cancer treatment portfolio.
The collaboration with Portage Biotech could potentially expand Merck's cancer treatment portfolio. The successful evaluation of Portage's adenosine antagonists in combination with KEYTRUDA could lead to new treatment options for patients with solid tumors, potentially driving Merck's revenues and stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Portage Biotech's collaboration with Merck to evaluate its next-generation adenosine antagonists in combination with KEYTRUDA could potentially enhance its product portfolio and market position.
The collaboration with Merck, a leading pharmaceutical company, could potentially enhance Portage Biotech's product portfolio and market position. The successful evaluation of its adenosine antagonists in combination with KEYTRUDA could lead to new treatment options for patients with solid tumors, potentially driving the company's revenues and stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100